top of page

Bi-weekly: Thursdays, 12 pm EDT/EST, 9 am PT/PST, 5 pm BST/BDT, 6 pm CEST/CET
https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ
Some seminars were recorded and accessible for a limited time on our youtube channel.

Upcoming Speakers

Cheryl Arrowsmith_current photo.png

October 10th, 2024

Host: Breanna Zerfas / Katherine Donovan

Cheryl Arrowsmith

University of Toronto

Time Change:
12 pm EDT/EST,
9 am PT/PST,
5 pm BST/BDT,
6 pm CEST/CET

Recruitment of FBX022 for Target Degradation.

Cheryl Arrowsmith is a Senior Scientist at the Princess Margaret Cancer Centre, Professor in the Department of Medical Biophysics, University of Toronto, and the Chief Scientist of the Structural Genomics Consortium (SGC) at the University of Toronto.  Her research focuses on the structural and chemical biology of chromatin and epigenetic regulatory factors especially as relates to cancer and drug discovery. In partnership with major pharmaceutical companies, she leads the SGC’s international open science program that is developing and distributing unencumbered Chemical Probes that support the

discovery of new medicines. She received her Ph.D. from the University of Toronto and carried out postdoctoral research at Stanford University, and was co-founder of Affinium Pharmaceuticals, which developed a new medicine for multidrug resistant bacteria. She has published over 300 research articles, and was recognized by Clarivate Analytics as being among the worlds top 1% of highly cited scientists in 2018, 2019, 2021, 2022. She was elected an AAAS Fellow (2015), and a Fellow of the Royal Society of Canada (2020).

Xiaoyu.jpg

Xiaoyu Zhang

Northwestern University

A CRISPR activation screen identifies FBXO22 supporting targeted protein degradation

Xiaoyu Zhang received his B.S. and M.S. degrees at Zhejiang University. He obtained his Ph.D. degree in Biochemistry and Chemical Biology from Cornell University, where he studied with Professor Hening Lin and demonstrated lysine fatty-acylation as an abundant and physiologically relevant protein posttranslational modification. As a Damon Runyon fellow at The Scripps Research Institute, he conducted his postdoctoral research with Professor Benjamin Cravatt and developed a proteomic platform to discover novel E3 ligases that support targeted protein degradation. In 2022, Xiaoyu started his independent career as an assistant professor at Northwestern University. His research group integrates chemical proteomics, functional genomics and chemical genetics to discover small molecules that modulate protein functions through novel mechanisms.

Bartlett_DFCI_TPD_photo.JPG

October 24th, 2024

Host: Zuzanna Kozicka

Derek Bartlett

University of North Carolina

PK-PD modeling for targeted protein degradation

Derek Bartlett is an assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics within the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. He received a BS degree in chemical engineering from Stanford University and MS and PhD degrees in chemical engineering from Caltech. Following completion of postdoctoral training in cancer immunotherapeutics and tumor immunology at City of Hope, he spent 15 years working within the pharmaceutical industry across a variety of functions including formulation, process development, and quantitative pharmacology. While at Pfizer, he led the creation of pharmacokinetic (PK)-pharmacodynamic (PD) model frameworks to support the targeted protein degradation portfolio. His research laboratory at UNC combines mechanistic modeling and dynamic cell-based assays as an animal-alternative approach to improve the translatability of preclinical studies and to unlock the potential of functional precision medicine through in vitro/ex vivo drug testing and dose optimization.

mangano.png

Kyle Mangano

Amgen

VIPER-TACs leverage viral E3 ligases for disease-specific targeted protein degradation.

Kyle Mangano is a native Rhode Islander who received his bachelor’s degree from McGill University. He leveraged his proximity to Cambridge, MA to work at two small biotechnology companies developing stapled peptides and nanoparticles, respectively. He then obtained his PhD from the University of Illinois at Chicago in Pharmaceutical Sciences. His graduate studies focused on the elucidating the mechanism of action of protein synthesis inhibitors using next generation sequencing. Kyle joined Amgen’s Induced Proximity Platform as a postdoctoral researcher in 2022, where he has been using chemical biology and genomic engineering to study targeted protein degradation.

November 7th, 2024

Host: Zuzanna Kozicka

Georg Winter

CeMM

When inhibitors degrade: supercharging of native protein turnover.

tba

bottom of page